A Long, Strange History
Humans have been exploring altered states for thousands of years. The story is not a simple arc of progress — it is cycles of discovery, suppression, and rediscovery.
Indigenous & Ceremonial Use
Psychoactive plants have been used in healing, divination, and ceremony across virtually every continent. These substances were never 'recreational' in the modern sense. They were medicines, teachers, and doorways to the sacred, embedded in specific cultural containers that guided their use.
Peyote & the Huichol
The Huichol (Wixárika) people of Mexico have used peyote in ceremonial pilgrimages to Wirikuta for centuries, perhaps millennia. The cactus is not consumed casually — it is hunted, prepared, and integrated into a sacred geography that gives the experience its shape.
Psilocybin in Mesoamerica
Aztec and Mazatec cultures used teonanácatl — 'flesh of the gods' — in healing and divinatory rituals. María Sabina, a Mazatec curandera, introduced psilocybin mushrooms to the Western world in 1955, a meeting that would alter the course of psychedelic history.
Ayahuasca Traditions
Indigenous peoples of the Amazon basin have brewed ayahuasca — a synergistic combination of DMT-containing chacruna and harmala-rich caapi vine — for centuries, perhaps longer. The brew is legal and protected as cultural patrimony in several South American nations.
Amanita muscaria & Beyond
From Siberian shamanic use of the red-and-white fly agaric to the possibly psychedelic kykeon of the Greek Eleusinian Mysteries, humans have found ways to alter consciousness in virtually every ecosystem and epoch.
The Research Boom
Albert Hofmann synthesizes LSD at Sandoz Laboratories in 1943 and accidentally discovers its effects. The 1950s and 60s see an explosion of psychiatric research that would not be rivaled for half a century.
Hofmann & Sandoz
On April 16, 1943, Albert Hofmann intentionally ingests 250 micrograms of LSD-25 — the first acid trip. Sandoz distributes the compound to researchers worldwide as Delysid, hoping to find therapeutic applications.
Psychiatric Innovation
Humphry Osmond treats alcoholism with LSD in Saskatchewan, coining the term 'psychedelic.' Stanislav Grof conducts thousands of LSD-assisted therapy sessions in Czechoslovakia. Harold Abramson explores LSD for autism and schizophrenia.
The Good Friday Experiment
In 1962, Walter Pahnke administers psilocybin to divinity students during a Good Friday service. Nine of ten recipients report a profound mystical experience — one of the first rigorous demonstrations that psychedelics can occasion genuine mystical states.
Harvard & the Counterculture
Timothy Leary and Richard Alpert (later Ram Dass) launch the Harvard Psilocybin Project. Leary's evangelism and advocacy for widespread use alienates the medical establishment and helps precipitate the backlash to come.
Prohibition & The Freeze
In 1970, the US Controlled Substances Act classifies LSD and psilocybin as Schedule I. Research funding evaporates. Most clinical programs shut down. For three decades, rigorous psychedelic science is effectively frozen.
The Controlled Substances Act
The 1970 CSA places LSD, psilocybin, mescaline, and later MDMA in Schedule I — 'no accepted medical use and high potential for abuse.' This classification makes research prohibitively expensive and legally complex, effectively halting the momentum of the 1960s.
The Lost Decades
A few researchers persist in underground or international settings — George Greer conducts MDMA-assisted therapy before it becomes illegal; Rick Doblin founds MAPS in 1986 to pursue MDMA research through legal channels. But for most of psychiatry, psychedelics become a dead letter.
Cultural Amnesia
The cultural narrative shifts from 'promising psychiatric tool' to 'dangerous hippie drug.' A generation of psychiatrists is trained without any exposure to psychedelic therapy. The promising clinical results of the 1950s and 60s gather dust in forgotten journals.
The Underground Persists
While formal research stalls, indigenous ceremonies continue uninterrupted. Underground therapists maintain quiet practices. Raves and electronic dance culture revive MDMA use outside medical frameworks. The flame never fully goes out — it just burns in different places.
The Renaissance
Roland Griffiths' 2006 Johns Hopkins study on psilocybin and mystical experience reopens the door. What follows is a rapid expansion of research, policy experimentation, and cultural normalization that continues to accelerate.
Griffiths Reopens the Door
Roland Griffiths' 2006 Johns Hopkins study demonstrates that psilocybin can occasion mystical-type experiences with sustained personal and spiritual significance. The methodology is rigorous, the results are striking, and the field is reborn.
MAPS & MDMA for PTSD
The Multidisciplinary Association for Psychedelic Studies completes Phase 3 trials of MDMA-assisted therapy for PTSD, showing dramatic efficacy. The FDA grants Breakthrough Therapy designation. The path to potential approval is cleared — then complicated by the FDA's 2024 rejection of the initial application.
Policy Experiments
Oregon legalizes supervised psilocybin services. Colorado follows. Several cities decriminalize personal possession. Australia approves prescription psilocybin for treatment-resistant depression. The policy landscape fragments into a patchwork of local experiments.
Breakthrough Designations & Investment
Compass Pathways, Usona Institute, and others receive FDA Breakthrough Therapy designations for psilocybin. Venture capital floods the space. The risk shifts from 'can this ever be legal?' to 'can the hype be matched by the evidence?'
The April 2026 Executive Order
A US executive order directs the FDA to issue National Priority Vouchers to psychedelics with Breakthrough Therapy designations, establishes an FDA-DEA pathway for investigational access under Right to Try, and creates a $50 million federal-state research matching fund. Substances remain Schedule I. The evidence bar is unchanged. But the signal is unmistakable: the renaissance has reached the White House.
The renaissance is real. It is also fragile. The same forces that shut down research in 1970 — political backlash, moral panic, reckless advocacy — could do it again. The best protection for this work is honest science, ethical practice, and a clear-eyed understanding of both the promise and the risks.
Read our mission